Agios Pharmaceuticals (NASDAQ:AGIO) Receiving Somewhat Favorable Press Coverage, Report Finds
News coverage about Agios Pharmaceuticals (NASDAQ:AGIO) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Agios Pharmaceuticals earned a news impact score of 0.24 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 50 out of 100, meaning that recent news coverage is somewhat likely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Upgraded to “Buy” by BidaskClub (americanbankingnews.com)
- Zacks: Brokerages Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $11.52 Million (americanbankingnews.com)
- Agios Pharmaceuticals Inc (AGIO) Showing Positive Momentum in the Technicals – Evergreen Caller (evergreencaller.com)
- Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) versus Jack in the Box Inc. (NasdaqGS:JACK) Technicals Update: A … – Evergreen Caller (evergreencaller.com)
- Blue Chip Partners Inc. Sells 775 Shares of Emerson Electric Company (EMR) (latribunadecanarias.com)
Several research analysts recently commented on the company. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. Janney Montgomery Scott lowered Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, June 26th. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, June 11th. Finally, Cann reiterated a “buy” rating and issued a $75.00 price target on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $62.88.
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) opened at 57.81 on Monday. The company’s market cap is $2.79 billion. Agios Pharmaceuticals has a 52 week low of $35.84 and a 52 week high of $67.74. The firm has a 50-day moving average of $51.10 and a 200 day moving average of $49.19.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, beating the consensus estimate of ($1.80) by $0.24. Agios Pharmaceuticals had a negative net margin of 491.54% and a negative return on equity of 71.20%. The business had revenue of $10.51 million during the quarter, compared to analysts’ expectations of $9.65 million. During the same quarter in the prior year, the company posted ($0.64) EPS. The business’s revenue for the quarter was down 66.4% on a year-over-year basis. Equities analysts expect that Agios Pharmaceuticals will post ($6.44) EPS for the current fiscal year.
In other news, insider Scott Biller sold 4,292 shares of the stock in a transaction that occurred on Wednesday, June 21st. The shares were sold at an average price of $55.00, for a total value of $236,060.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 2,000 shares of the stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $50.87, for a total transaction of $101,740.00. Following the completion of the sale, the director now directly owns 90,197 shares of the company’s stock, valued at approximately $4,588,321.39. The disclosure for this sale can be found here. In the last three months, insiders sold 24,564 shares of company stock valued at $1,282,249. Corporate insiders own 10.55% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Agios Pharmaceuticals (NASDAQ:AGIO) Receiving Somewhat Favorable Press Coverage, Report Finds” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/07/17/agios-pharmaceuticals-nasdaqagio-receiving-somewhat-favorable-press-coverage-report-finds.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.